Stephen Schondelmeyer, PharmD, PhD

Stephen Schondelmeyer

Weaver-Densford Hall, Room 7-159
Minneapolis, MN 55455
United States


Dr. Schondelmeyer is a professor of Pharmaceutical Economics in the College of Pharmacy at the University of Minnesota where he holds the Century Mortar Club Endowed Chair in Pharmaceutical Management & Economics. Dr. Schondelmeyer is the Director of the PRIME Institute, which focuses on pharmaceutical research related to management and economics.


Dr. Schondelmeyer's education, experience, and background provide him with a unique understanding of the complex and technical issues leading to dramatic changes in the pharmaceutical marketplace. His expertise includes pharmacy practice management, prescription drug reimbursement, drug benefit plan management, pricing patterns of the pharmaceutical industry, and pharmacoeconomics and outcomes management. His work experience has encompassed activities in practice, academia, professional associations, and state and federal government.


Professor, Department of Pharmaceutical Care & Health Systems

Affiliate Faculty, Institute for Health Informatics

Director, PRIME Institute

Endowed Chair, Pharmaceutical Management & Economics, Century Mortar Club

Residency, University of Kentucky (ASHP Residency), 1974-1977

Fellowship, Ohio State University (National Endowment for Humanities), 1976

PhD, Ohio State University (Social & Administrative Pharmacy) (Major: Health Economics; Minor: Behavioral Epidemiology), 1984

Doctor of Pharmacy, University of Kentucky, 1977

Masters Degree, Ohio State University (Public Administration), 1979

Bachelors Degree, University of Missouri-Kansas City (Pharmacy), 1974


Expand all


Research Summary/Interests

Dr. Schondelmeyer has conducted policy analysis in many areas such as reimbursement of prescription drugs under Medicaid, Medicare, managed care and other third party programs. He was appointed to the Prescription Drug Payment Review Commission, which served in an oversight and advisory capacity to Congress for the now repealed Medicare Catastrophic Coverage Act of 1988 outpatient drug program. He has conducted research projects for a variety of sponsors including: the Centers for Medicare & Medicaid Services (CMS), the U.S. Government Accountability Office (GAO), the Congressional Office of Technology Assessment (OTA), the U.S. Senate Special Committee on Aging, the Food and Drug Administration (FDA), the pharmaceutical industry, and pharmacy associations.

  • Public policy related to prescription drug coverage in Medicare and Medicaid
  • Drug benefit design and coverage in managed care and private insurance plans
  • Economics, competition, structure and organization of the pharmaceutical market
  • Affordability and access to drug therapy and pharmaceutical care
  • Pharmacoeconomics and outcomes assessment


For a list of publications, see PubMed.



Phar 6131: Pharmacy & Health Care Systems; SAPh 8235: Pharmaceutical Economics & Policy